Table 3 Univariate and multivariate analyses for prognostic factors of AC benefit through the transformation model

Gender

Male/female

0.059

2.786 (0.962–8.068)

0.069

3.374 (0.908–12.538)

0.251

2.071 (0.598–7.174)

0.204

2.513 (0.606–10.421)

Age

< 60/ ≥ 60

0.820

0.909 (0.401–2.063)

0.873

0.932 (0.392–2.213)

ECOG Scoring

0/1–2

0.249

0.624 (0.280–1.391)

0.743

1.151 (0.497–2.666)

Tumor location

Up/down

0.115

0.520 (0.231–1.173)

0.212

0.585 (0.253–1.356)

Clinical stage

II–III/IV

0.001

0.208 (0.082–0.531)

0.102

0.485 (0.204–1.156)

1.000

T stage

T2-3/T4

0.139

0.423 (0.135–1.324)

0.050

0.335 (0.112–1.001)

0.064

0.304 (0.086–1.070)

N stage

N0-1/N2-3

0.002

0.240 (0.097–0.596)

0.141

0.523 (0.221–1.240)

1.000

Radiation dose

< 59.4 Gy/ ≥ 59.4 Gy

0.444

1.438 (0.568–3.641)

0.177

1.913 (0.746–4.903)

MacroType

Fungating + Ulcer/Medulla + Constrictive

0.129

0.538 (0.242–1.197)

0.004

0.280 (0.116–0.673)

0.005

0.246 (0.092–0.661)

CT Regimen

PF/TP

0.893

0.947 (0.428–2.093)

0.962

1.020 (0.443–2.352)

Target Delineation

ENI/IFI

0.922

1.040 (0.473–2.288)

0.726

1.160 (0.506–2.662)

Short-term response

Good/poor

< 0.001

5.500 (2.305–13.126)

< 0.001

5.029 (2.039–12.399)

< 0.001

5.969 (2.258–15.776)

0.003

4.395 (1.650–11.710)